William Blair Reiterates Outperform Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)
William Blair restated their outperform rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report released on Tuesday morning,RTT News reports. William Blair also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.95 EPS, Q3 2025 earnings at $4.16 EPS and Q4 2025 earnings at $4.54 EPS. Other research analysts […]
William Blair restated their outperform rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report released on Tuesday morning,RTT News reports. William Blair also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.95 EPS, Q3 2025 earnings at $4.16 EPS and Q4 2025 earnings at $4.54 EPS. Other research analysts […]
